Please ensure Javascript is enabled for purposes of website accessibility

Why Agenus Stock Skyrocketed Today

By Keith Speights - May 18, 2021 at 4:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech announced a big licensing deal with Bristol Myers Squibb.

What happened

Shares of Agenus (AGEN 11.24%) skyrocketed 20.6% on Tuesday. The big gain came after the company announced a deal to license bispecific antibody program AGEN1777 to Bristol Myers Squibb (BMY 1.49%)

So what

What really lit a fire under the biotech stock from today's news was just how much Bristol Myers Squibb was willing to fork over for rights to AGEN1777. The big drugmaker is paying Agenus $200 million upfront. Agenus also stands to receive up to $1.36 billion in milestones as well as tiered double-digit royalties on potential sales for the product.

Hands shaking in front of $100 bills

Image source: Getty Images.

AGEN1777 hasn't advanced into clinical testing yet. However, the experimental therapy has demonstrated promise in preclinical studies in treating tumors where anti-PD-1 or anti-TIGIT antibodies aren't effective by themselves. 

Now what

Agenus plans to file an Investigational New Drug (IND) application by June 30, 2021, to begin an early stage clinical study of AGEN1777. Bristol Myers Squibb expects to explore the use of the experimental therapy in treating non-small cell lung cancer as well as other high-priority indications.

Keith Speights owns shares of Bristol Myers Squibb. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Agenus Inc. Stock Quote
Agenus Inc.
AGEN
$2.97 (11.24%) $0.30
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$75.57 (1.49%) $1.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.